These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

815 related articles for article (PubMed ID: 29626068)

  • 21. Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data.
    Qamar A; Giugliano RP; Keech AC; Kuder JF; Murphy SA; Kurtz CE; Wasserman SM; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2019 Jan; 4(1):59-63. PubMed ID: 30540337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
    Giugliano RP; Pedersen TR; Park JG; De Ferrari GM; Gaciong ZA; Ceska R; Toth K; Gouni-Berthold I; Lopez-Miranda J; Schiele F; Mach F; Ott BR; Kanevsky E; Pineda AL; Somaratne R; Wasserman SM; Keech AC; Sever PS; Sabatine MS;
    Lancet; 2017 Oct; 390(10106):1962-1971. PubMed ID: 28859947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of PCSK9 inhibitor (evolocumab) in patients with non-ST segment elevation acute coronary syndrome and non-culprit artery critical lesions: a randomised controlled trial protocol (SPECIAL study).
    Wang YW; Xu J; Ma L; Hu H; Chen HW; Hua JS; Kong XY; Li D; Li LW; Pan JY; Wu J
    BMJ Open; 2024 Jul; 14(7):e083730. PubMed ID: 39009458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization.
    Oyama K; Furtado RHM; Fagundes A; Zelniker TA; Tang M; Kuder J; Murphy SA; Hamer A; Wang H; Keech AC; Giugliano RP; Sabatine MS; Bergmark BA
    J Am Coll Cardiol; 2021 Jan; 77(3):259-267. PubMed ID: 33197560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies.
    Raal FJ; Hegele RA; Ruzza A; López JAG; Bhatia AK; Wu J; Wang H; Gaudet D; Wiegman A; Wang J; Santos RD
    Arterioscler Thromb Vasc Biol; 2024 May; 44(5):1156-1164. PubMed ID: 38545781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial.
    Damask A; Steg PG; Schwartz GG; Szarek M; Hagström E; Badimon L; Chapman MJ; Boileau C; Tsimikas S; Ginsberg HN; Banerjee P; Manvelian G; Pordy R; Hess S; Overton JD; Lotta LA; Yancopoulos GD; Abecasis GR; Baras A; Paulding C;
    Circulation; 2020 Feb; 141(8):624-636. PubMed ID: 31707832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
    Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
    Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolocumab, a PCSK9-Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia.
    Leucker TM; Gerstenblith G; Schär M; Brown TT; Jones SR; Afework Y; Weiss RG; Hays AG
    J Am Heart Assoc; 2020 Jul; 9(14):e016263. PubMed ID: 32674634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial.
    Bohula EA; Marston NA; Ruzza A; Murphy SA; De Ferrari GM; Diaz R; Leiter LA; Elliott-Davey M; Wang H; Bhatia AK; Giugliano RP; Sabatine MS
    Am Heart J; 2024 Mar; 269():179-190. PubMed ID: 38160917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes.
    Taskinen MR; Björnson E; Kahri J; Söderlund S; Matikainen N; Porthan K; Ainola M; Hakkarainen A; Lundbom N; Fermanelli V; Fuchs J; Thorsell A; Kronenberg F; Andersson L; Adiels M; Packard CJ; Borén J
    Arterioscler Thromb Vasc Biol; 2021 Feb; 41(2):962-975. PubMed ID: 33356392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
    Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJ; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Scott R; Ungi I; Podolec J; Ophuis AO; Cornel JH; Borgman M; Brennan DM; Nissen SE
    JAMA; 2016 Dec; 316(22):2373-2384. PubMed ID: 27846344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
    Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial.
    Deedwania P; Murphy SA; Scheen A; Badariene J; Pineda AL; Honarpour N; Keech AC; Sever PS; Pedersen TR; Sabatine MS; Giugliano RP
    JAMA Cardiol; 2021 Feb; 6(2):139-147. PubMed ID: 32785614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduction of cardiovascular risk with evolocumab (Repatha).
    Med Lett Drugs Ther; 2017 Apr; 59(1519):63-64. PubMed ID: 28419071
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials.
    Kereiakes DJ; Lepor NE; Gerber R; Veronica Lee L; Elassal J; Thompson D; Michael Gibson C
    Atherosclerosis; 2018 Oct; 277():211-218. PubMed ID: 30025648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial.
    Sabatine MS; Giugliano RP; Keech A; Honarpour N; Wang H; Liu T; Wasserman SM; Scott R; Sever PS; Pedersen TR
    Am Heart J; 2016 Mar; 173():94-101. PubMed ID: 26920601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial.
    Bergmark BA; O'Donoghue ML; Murphy SA; Kuder JF; Ezhov MV; Ceška R; Gouni-Berthold I; Jensen HK; Tokgozoglu SL; Mach F; Huber K; Gaciong Z; Lewis BS; Schiele F; Jukema JW; Pedersen TR; Giugliano RP; Sabatine MS
    JAMA Cardiol; 2020 Jun; 5(6):709-713. PubMed ID: 32347887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low Density Lipoprotein (LDL) Cholesterol as a Causal Role for Atherosclerotic Disease: Potential Role of PCSK9 Inhibitors.
    Del Pinto R; Grassi D; Properzi G; Desideri G; Ferri C
    High Blood Press Cardiovasc Prev; 2019 Jun; 26(3):199-207. PubMed ID: 31236902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
    Auer J; Berent R
    Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.